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We showed that docosahexaenoic acid (DHA) supplementation during pregnancy and lactation was
associated with more mildly abnormal (MA) general movements (GMs) in the infants. Since this ﬁnding
was unexpected and inter-individual DHA intakes are highly variable, we explored the relationship
between GM quality and erythrocyte DHA, arachidonic acid (AA), DHA/AA and Mead acid in 57 infants
of this trial. MA GMs were inversely related to AA, associated with Mead acid, and associated with DHA/
AA in a U-shaped manner. These relationships may indicate dependence of newborn AA status on
synthesis from linoleic acid. This becomes restricted during the intrauterine period by abundant de novo
synthesis of oleic and Mead acids from glucose, consistent with reduced insulin sensitivity during the
third trimester. The descending part of the U-shaped relation between MA GMs and DHA/AA probably
indicates DHA shortage next to AA shortage. The ascending part may reﬂect a different developmental
trajectory that is not necessarily unfavorable.
& 2009 Elsevier Ltd. All rights reserved.1. Introduction
The long chain polyunsaturated fatty acids (LCP) arachidonic
acid (AA; 20:4n6), eicosapentaenoic acid (EPA; 20:5n3) and
docosahexaenoic acid (DHA; 22:6n3) are structural components
of membrane phospholipids, modulators of gene expression and
precursors of eicosanoids (AA, EPA), resolvins (AA, EPA and DHA)
and (neuro)protectins (DHA) [1,2]. EPA and DHA are mainly
derived from ﬁsh, while meat, poultry and eggs are the main
sources of dietary AA. Both AA and DHA are considered important
for brain development.
We recently reported results of supplementing healthy
pregnant women with DHA+AA (220 mg each/day), DHA
(220 mg/day) or placebo from week 17 of pregnancy till 12 weeks
after term delivery. The primary endpoint was the infants general
movement (GM) quality [3]. GMs are movements involving all
body parts, they are characterized by variation, complexity and
ﬂuency [4]. They emerge during early fetal life and disappear at
about 4 months post-term when goal-directed movementsll rights reserved.
d Campina, The Netherlands.
ter Groningen, EA22; CMC-V,
etherlands,
90.
an Goor).emerge. The typical characteristics of GMs disappear in case of
dysfunction [5]. General movements can be qualiﬁed as normal
optimal (NO), normal suboptimal (NS), mildly abnormal (MA) or
as deﬁnitely abnormal (DA), of which the latter is considered to be
of clinical relevance [5]. Our study revealed that infants in the
DHA group showed more MA GMs as compared to the placebo
group and the DHA+AA group, whereas the placebo and DHA+AA
groups did not differ in GM quality.
The ﬁnding that DHA supplementation resulted in more MA
GMs was unexpected, since generally DHA status is positively
associated with neurological development, although reviews and
meta analyses [6–8] of DHA supplementation studies show no
effect or are at best inconclusive. We hypothesized that GM
quality is sensitive to the DHA/AA balance. Alternatively, the
relation between maternal DHA intake and parameters for
neurological development of their offspring may be non-linear,
for which there is some evidence from studies in rats [9] and
humans [10]. Moreover, ﬁsh consumption is subject to high inter-
individual variation and consequently, at the study end, subjects
with low background intakes in the intervention group may have
a DHA status similar to, or even lower than, that of subjects with
high background DHA intakes residing in the placebo group.
In view of the unexpectancy of the outcome of our trial and the
highly variable inter-individual DHA status, we studied the
relation between the LCP status at the study end and neurological
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the infant’s GM quality at 12 weeks of age with the infant’s red
blood cell (RBC) DHA, AA and Mead acid (20:3n9; parameter of
EFA/LCP deﬁciency) contents, as well as the RBC DHA/AA ratio.Table 1
Prenatal, perinatal and social characteristics of the 57 mother–infants pairs
included in the study.
N GMs (n=30) MA GMs (n=27)
Maternal age (y) (mean7sd) 32.774.4 29.473.6n
Maternal higher educationa [n(%)] 28 (93) 18 (67)n
First born [n(%)] 17 (57) 13 (48)
Gestational age at birth (wk) (mean7sd) 40.570.9 40.071.4
Gender male [n(%)] 17 (57) 10 (37)
Birth weight (g) (mean7sd) 36897440 34637471
Exclusively breastfed infantsb [n(%)] 18 (60) 18 (67)
N GMs, normal general movements; MA GMs, mildly abnormal general move-
ments; ndifferent from normal GMs at po0.05; ahigh school completed; bat time
of examination (12 postnatal weeks).2. Subjects and methods
The study design has been reported in detail elsewhere [3].
Brieﬂy, healthy women during their ﬁrst or second pregnancy, were
enrolled around week 17 of pregnancy (mean: 16.5 weeks
postmenstrual age). Exclusion and termination criteria were a
vegan diet, (gestational) diabetes mellitus and preterm birth (before
37 weeks of pregnancy). At enrolment, women were randomized to
three groups. All participants received a vitamin and mineral
supplement containing the Dutch recommended dietary allowance
for pregnant women. In addition, the women received placebo (soy
bean oil), DHA (220 mg/day) or DHA+AA (220 mg each/day). The
research protocol was approved by the Central Committee on
Research Involving Human Subjects (CCMO, Den Haag, The Nether-
lands; protocol number P03.1071C). All women gave written
informed consent. The trial is registered under ISRCTN58176213.
2.1. Neurological examination
The infant’s neurological condition was assessed by establish-
ing the GM quality in the 12th postnatal week. To this end,
spontaneous motility in supine position was videotaped for at
least 5 min. Movements were recorded while the infant was
awake, active and not crying. GM quality was assessed according
to Hadders-Algra et al. [11], i.e. movements were classiﬁed as
normal optimal (NO), normal suboptimal (NS), mildly abnormal
(MA) or deﬁnitely abnormal (DA).
2.2. Characteristics
We used the Obstetrical Optimality Score (OOS) form to obtain
data on socioeconomic status, non-obstetrical conditions during
pregnancy, obstetrical past history, diagnostic and therapeutic
measures, parturition and neonatal condition immediately after
birth [12].
2.3. Sample collection and fatty acid analyses
EDTA-anticoagulated blood from the infants was collected
12 weeks after birth, for the isolation of RBC (throughout referred to
as infant RBC; iRBC) After washing the RBC three times with 0.9%
saline, 200 mL of a 50% hematocrit suspension was transferred
into a Sovirel tube. The Sovirel tubes contained 2 mL methanol/
HCl (5:1, v/v), 5 mg butylated hydroxytoluene (antioxidant) and
50 mg 17:0 (internal quantiﬁcation standard). Following trans-
methylation, fatty acid compositions were determined by using
our previously described capillary gas chromatographic method
with ﬂame-ionization detection [13]. Fatty acid compositions
were calculated assuming that equal peak areas give rise to equal
weight amounts [14]. Fatty acids are presented in wt% or wt/wt.
We focused on DHA, AA, Mead acid and the DHA/AA ratio.
2.4. Statistical analyses
Statistics were performed using the software package SPSS,
version 16. Univariate differences for perinatal and social
characteristics were evaluated by using either a chi-square test
(for categorical variables) or a t-test (for continuous variables). For
DHA, AA, DHA/AA and Mead acid, we created univariate logisticregression models. To test whether there were non-linear
relations between fatty acids and GM-quality, we added a
quadratic term to the model to test for U-shape or bell-shape. In
case changes in GM-quality seemed to reach a plateau at a certain
wt%, we dichotomized the continuous variable at the plateau
level. We also created a multivariate logistic regression model
with GM quality as dependent variable and the fatty acids as well
as relevant perinatal and social characteristics as covariates to
study which variables are most predictive for GM quality. po0.05
was considered signiﬁcant.
3. Results
A total of 183 pregnant women were included. Of these, GM
quality and perinatal data were available from 119 mother–infant
pairs. Blood samples were collected from 57 infants. Reasons for
drop-out were lack of motivation to take supplements daily and
to ﬁll in questionnaires on a regular basis (58 cases), preterm
delivery (4 cases), other pregnancy complications (2 cases) and no
parental permission for infant blood sampling (62 cases). There
were no differences in GM quality and prenatal, perinatal or social
characteristics between the infants of whom blood was collected
compared to those of whom blood was not available (data not
shown). All cases of drop-out were evenly distributed among the
three treatment groups.
Table 1 shows prenatal, perinatal and social characteristics of
the 57 mother–infant pairs who were included in this study. For
statistical purposes, we recoded NO and NS GMs into normal (N)
GMs. None of the infants showed DA GMs. Thirty infants were
classiﬁed as having normal GMs (3 NO and 27 NS GMs) and 27
had MA GMs. Mothers of infants with MA GMs were younger and
had a lower educational level (po0.05), they did not differ in
parity. Infants with N GMs did not differ in gender, birth weight
and gestational age at birth from infants with MA GMs. Frequency
of exclusive breastfeeding was similar in the two groups.
Fig. 1 shows the percentages MA GMs as functions of iRBC DHA
(panel A), AA (panel B), DHA/AA ratio (panel C) and Mead acid
(panel D). The iRBC data were clustered into sixtiles for visual
evaluation. Univariate analysis revealed that there was no
signiﬁcant relation between GM quality and DHA status. A
higher iRBC AA was associated with less MA GMs (Nagelkerke r2
0.12; model chi2 5.39; model p=0.020). The iRBC DHA/AA ratio
was related to the occurrence of MA GMs in a U-shaped manner,
i.e. both low and high iRBC DHA/AA ratios were associated with
high rates of MA GMs (Nagelkerke r2 0.20; model chi2 9.03; model
p=0.011). The lowest percentage MA GMs (about 25%) was
observed at iRBC DHA/AA ratios ranging from 0.32–0.36 (wt/wt).
An increasing iRBC Mead acid was associated with an increasing
rate of MA GMs, a 60–70% MA GMs plateau was reached at an iRBC
Mead acid of about 0.40 wt% (Nagelkerke r2 0.24; model chi2
11.25; model p=0.001).
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Fig. 1. Percentage infants with mildly abnormal GMs as a function of iRBC DHA, AA, DHA/AA and Mead acid. MA GMs, mildly abnormal general movements. There is no
signiﬁcant relation between DHA and GM quality. MA GMs are inversely related to AA, are associated with Mead acid, and are associated with DHA/AA in a U-shaped
manner. The U-shaped curve does not imply an optimum at 0.32–0.33 DHA/AA, but might indicate a different developmental trajectory at the ascending part of the curve,
which is not necessarily unfavorable.
Table 2
Logistic regression analyses of factors contributing to the rate of mildly abnormal
GMs in the 12th postnatal week.
Exp B (95% CI) p
iRBC Mead acid (g%)a 11.80 (2.57–54.21) 0.002
Maternal age at baseline (y) 0.78 (0.64–0.95) 0.013
Maternal educationb 0.11 (0.01–0.89) 0.039
Constant 4154.46 0.011
Factors were considered to be signiﬁcant at po0.05. Explained variance of the
model 49.1% (Nagelkerke), model chi2, 26.1; po0.001. aDichotomized at 0.40 g%;
0o0.40 g%, 1Z0.40 g%; b0=lower education, 1=higher education, i.e. high school
completed. CI, conﬁdence interval; iRBC, infant red blood cell at 12 weeks of age.
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regression analyses. iRBC Mead acid values above 0.40 wt% were
associated with increased odds of MA GMs, whereas both higher
maternal age and higher maternal education were associated with
decreased odds of MA GMs.4. Discussion
We studied the relations between the iRBC DHA, AA and Mead
acid contents, and the iRBC DHA/AA ratio on the one hand and GMquality at 3 months of age on the other hand. The percentage MA
GMs proved: (1) inversely related to iRBC AA, (2) associated with
iRBC Mead acid according to a saturation curve and (3) associated
to the iRBC DHA/AA ratio in a U-shaped manner. In multivariate
logistic regression, iRBC Mead acid proved strongest related to GM
quality and to a lesser extent with maternal age and maternal
education. The strength of the study is the employment of a
sensitive method for the assessment of neurodevelopment, while
it is limited by the relatively small number of infants, which,
however, did not hamper the observational power of the study.
The relation between GM quality and AA status is in
accordance with a previous study from our group [15], in which
GM quality also proved positively associated with AA and
negatively with total n-9 fatty acids and oleic acid (OA, 18:1n-9)
contents and the Mead acid/AA ratio of umbilical arteries. The
different directions of the relations of GM quality with AA and n-9
fatty acids are conceivable, since there are strong metabolic
relations between AA and OA, and between AA and Mead acid in
umbilical vessel walls [16]. In addition, Helland et al. found a
relation between umbilical plasma Mead acid and intelligence
scores at 4 years of age [17].
High iRBC Mead acid in the postnatal period is conceivably a
remnant of intrauterine conditions, since the initially high levels
at birth gradually disappear with advancing postnatal age [18].
The abundant intrauterine synthesis of Mead acid [19] is a
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glucose that crosses the placenta in the third trimester [20].
Together with other de novo synthesized fatty acids, OA
constitutes about 80% of the fatty acids that accumulate in the
newborn’s fat mass [21]. The fetus synthesizes abundant OA, but
receives limited fatty acids across the placenta [22] and is
inefﬁcient in trapping free linoleic acid (LA, 18:2n-6) as shown
at least in primates [23]. This contributes to a high fetal OA/LA
ratio that stimulates fetal delta-6 desaturase (FADS2) to synthe-
size Mead acid from OA, at the expense of AA from LA. Consistent
with this notion are the observations that Mead acid in umbilical
vessel walls exhibits a positive relation with OA, and negative
correlations with both AA and LA [16]. In addition there is
competition between Mead acid and AA for incorporation into
tissue lipids, since it was shown in rats that supplementation with
Mead acid causes displacement of AA, notably at low LA intakes
[24]. In other words, it seems that both fetal and early postnatal
Mead acid indicate intrauterine restricted AA synthesis and
incorporation.
Mead acid synthesis may become ampliﬁed by excessively
high fetal de novo fatty acid synthesis from glucose in the third
trimester due to abnormally low maternal insulin sensitivity. This
causes even more successful competition of de novo synthesized
OA for delta-6 desaturase and the occurrence of a state of ‘relative
EFA/LCP deﬁciency’, rather than an absolute deﬁciency [25]. Such
conditions have been encountered in maternal diabetes mellitus
type 2, gestational diabetes [25,26] and preeclampsia [27], which
may carry a common denominator in maternal insulin resistance.
The underlying mechanisms might be higher transplacental
glucose ﬂux with concomitantly increased fetal de novo fatty acid
synthesis in (gestational) diabetes, and highly increased de novo
fatty acid synthesis in the maternal liver [28] with subsequent
presentation of these fatty acids for transplacental transfer in
(gestational) diabetes and preeclampsia.
Abundant fetal Mead acid synthesis is unlikely to be a
consequence of insufﬁcient AA status and high de novo fatty acid
synthesis only. It also requires low DHA, since both AA and DHA
are known to cause feedback inhibition of delta-6 desaturase [29].
The origin of low fetal DHA is low maternal DHA, since DHA is
preferentially transported across the placenta, compared with AA,
ALA and LA [30]. The currently employed relatively low maternal
supplemental DHA dose (i.e. 220 mg/day), the insufﬁcient DHA
background intake by Dutch women (about 84 mg LCPn-3/day in
2003 [31]; Dutch recommendation 450 mg LCPn-3/day), the
decreasing LCPn-3 intake during the last decades in Western
countries in general [32], and depletion of maternal AA and
notably DHA during pregnancy and subsequent lactation [33] are
likely to result in marginal fetal DHA status. Although not deﬁned
for infants, none of the infants in our study complied with the
48 wt% RBC EPA+DHA as set by Von Schacky and Harris [34],
which criterion confers 90% less risk for sudden cardiac death in
adults, as compared to an omega-3 index of o4%. In addition,
only two of the DHA-supplemented mothers met this recommen-
dation (data not shown).
The relation of GM quality with DHA (Fig. 1, panels A and C)
proved different from the relation with AA. Generally, brain DHA
is more sensitive to dietary DHA than brain AA is to dietary AA,
which has been shown in baboons [35] and may also be derived
from autopsy studies in breast and formula fed infants [36–38].
The descending part of the U-shaped relation between GM quality
and the iRBC DHA/AA ratio (Fig. 1, panel C) may indicate a similar
adverse effect of low fetal DHA status as described above for AA.
Moreover, with decreasing DHA/AA ratio, or with decreasing DHA
status, brain development will become compromised, as notably
shown in animal studies [6]. It has been established that low brain
DHA/AA ratio is related to (neuro)inﬂammation [39].The ascending part of the U-shaped iRBC DHA/AA curve (Fig. 1,
panel C) is, however, likely to have a different explanation. It is
well known that the various parts of the fetal brain have different
DHA and AA contents and that not all parts are equally sensitive
to dietary DHA alterations. For instance, Hsieh et al. [35] showed
that the newborn baboon cerebral cortex DHA content still
increases at higher DHA intakes, while basal ganglia and limbic
system DHA already saturate at lower intakes. The ascending part
of the U-shaped curve, although indicating an increase of MA GM
quality with increasing DHA/AA ratio, does not exclude a
beneﬁcial effect of DHA for some parts of the brain and their
functions at later age, or may indicate a different developmental
trajectory. The beneﬁcial effects of a higher than current DHA
status is increasingly acknowledged, as may e.g. be derived from
the recent adjustment of the recommended daily intake of LCPn-3
from 200 to 450 mg, while there is a good evidence that even
higher intakes may be needed, at least for prevention of coronary
heart disease [40].
Interestingly, U- or bell-shaped curves similar to ours were
shown by Levant et al. [9] and Jacobson et al. [10]. Levant et al. [9]
showed that variation in rat brain DHA content by dietary means
caused sex-speciﬁc alterations in locomotor activity, with males
being most affected notably at post-adolescent age. The observed
DHA intake-effect curve proved bell-shaped, with both low and
high DHA intakes giving rise to lower locomotor activities
compared with control and medium low DHA intakes. Although
uncommented by the authors, Jacobson et al. [10] showed a
U-shaped relation between cord plasma phospholipid DHA and
the Bayley Scales Psychomotor Development Index (PDI) at 11
months in breastfed Inuit infants with high DHA intakes living in
the Arctic region. In addition, Church et al. [41] showed that
excess as well as deﬁcient n-3 fatty acid intakes during pregnancy
and lactation cause impaired neural transmission in rats [41]. In
human infants, negative associations between higher DHA intakes
and verbal skills have been reported [42,43].
What brain areas are involved in the ascending part of the
curve might become suggested from studies in newborn baboons.
These show that the brain motor areas are not only highest in
DHA (and AA) contents [44], but also the most sensitive to DHA
supplementation [35]. Experiments with young rats revealed that
ﬁsh oil supplementation inﬂuences several neurochemical and
behavioral features of monoaminergic function, causing an
increase of cerebral membrane phosphatidylserine, higher dopa-
mine, reduction of monoamineoxidase-B activity and greater
binding to dopamine D2 receptors in the frontal cortex, and also
lower ambulatory activity [45]. Taken together, these data suggest
that the U-shaped dose-response curves of the locomotion
parameters of Levant et al. [9], the PDI of Jacobson et al. [10]
and general movements (this study) have a common denominator
in the modulation of the developing motor areas by dietary DHA.
U-shaped dose-response curves are not uncommon [46]. Of
these, the effect of alcohol on coronary artery disease [47] is
probably best known, while also micronutrient dose-response
curves are classical examples [48]. The pathophysiological effects
in U-shaped curves in the descending (i.e. deﬁcient) and
ascending (i.e. toxicological) parts usually reﬂect different under-
lying mechanisms leading to the common denominator of
‘unfavorable effects’. Consequently, it is possible that the
descending and ascending parts of the iRBC DHA/AA dose-
response curve indicate different neurodevelopmental trajectories
that nevertheless are preceded by similar MA GMs. Within the
current iRBC DHA/AA range, these seemingly opposing develop-
mental trajectories are unlikely to cause different neurodevelop-
mental outcomes at later age, as suggested by the negative
outcomes of meta analyses of LCP supplementation studies
[6,8]. It is possible that within the currently investigated
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brain development.5. Conclusions
The assessment of GM quality proved a highly sensitive tool for
studying the inﬂuence of LCP on neurodevelopment, since no test
for neurodevelopment, apart from those assessing visual acuity,
has as yet proven to be comparably sensitive to changes in LCP
status. MA GM quality exhibits an inverse relationship with AA
status and a saturating positive relationship with Mead acid.
These relationships may indicate the dependence of newborn AA
status on synthesis from LA, which conversion becomes restricted
during the intrauterine period by de novo synthesis of OA and
Mead acid from glucose, consistent with the reduced maternal
insulin sensitivity of the third trimester. MA GM quality also
exhibits an inverse relation with the DHA/AA ratio, which
probably indicates DHA shortage next to AA shortage. However,
the latter relationship shows a nadir, after which the relation
becomes positive. We speculate that this ascending part of the U-
shaped dose-response curve reﬂects a different developmental
trajectory that might be related to motor areas and is not
necessarily unfavorable.Acknowledgements
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